Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01499355
Registration number
NCT01499355
Ethics application status
Date submitted
23/11/2011
Date registered
26/12/2011
Date last updated
18/01/2017
Titles & IDs
Public title
BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis
Query!
Secondary ID [1]
0
0
2011-002159-32
Query!
Secondary ID [2]
0
0
211LE201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ATLAS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lupus Nephritis
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - mycophenolate mofetil
Treatment: Drugs - oral corticosteroids
Placebo comparator: Placebo - Placebo intravenous (IV) infusion on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48, plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF)
Experimental: BIIB023 3 mg/kg - BIIB023 3 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
Experimental: BIIB023 20 mg/kg - BIIB023 20 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
Treatment: Drugs: mycophenolate mofetil
titrated to a target daily dose of 2 g (1 g twice daily)
Treatment: Drugs: oral corticosteroids
oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Achieve a Complete or Partial Renal Response at Week 52
Query!
Assessment method [1]
0
0
Complete renal response is defined as: (1) urinary protein:creatinine ratio (uPCR) \< 0.5 mg/mg with = 50% reduction of uPCR from Day 1 (Baseline; from a 24 hour urine collection); and (2) estimated glomerular filtration rate (eGFR) within normal range. Partial renal response is defined as: (1) = 50% reduction in uPCR from Day 1 (Baseline; from a 24-hour urine collection) and, (2) with one of the following: (a) uPCR of \< 1.0 mg/mg if the Day 1 (Baseline) was = 3.0 mg/mg, or, (b) uPCR \< 3.0 mg/mg if the Day 1 (Baseline) ratio was \> 3.0 mg/mg; and stabilization of renal function (eGFR + or - 25% of Day 1 \[Baseline\] or serum creatinine within normal range).
Query!
Timepoint [1]
0
0
Week 52
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Achieve Complete Renal Response at Week 52
Query!
Assessment method [1]
0
0
Complete renal response is defined as uPCR \< 0.5 mg/mg with = 50% reduction of uPCR from Baseline (from a 24-hour urine collection) and eGFR within normal range.
Query!
Timepoint [1]
0
0
Week 52
Query!
Secondary outcome [2]
0
0
Duration of Renal Response in Participants Who Achieve Complete Renal Response at Week 52
Query!
Assessment method [2]
0
0
Duration of response was calculated as the days in between the date of Week 52 visit and the date when the participant last became complete renal responder on or before Week 52 visit. Complete renal response: (1) uPCR \<0.5 mg/mg with = 50% reduction of uPCR from Day 1 (Baseline) (from a 24 hour urine collection); and (2) eGFR within normal range.
Query!
Timepoint [2]
0
0
Week 52
Query!
Secondary outcome [3]
0
0
Time to Renal Response (Partial or Complete) in Participants Who Achieve Renal Response at Week 52
Query!
Assessment method [3]
0
0
Onset of renal response was calculated as weeks elapsed from baseline date to first visit where renal response was achieved. Complete renal response is defined as: (1) uPCR \<0.5 mg/mg with = 50% reduction of uPCR from Day 1 (Baseline) (from a 24 hour urine collection); and (2) eGFR within normal range. Partial renal response is defined as: (1) = 50% reduction in uPCR from Day 1 (Baseline; from a 24-hour urine collection) and, (2) with one of the following: (a) uPCR of \< 1.0 mg/mg if the Day 1 (Baseline) was = 3.0 mg/mg, or, (b) uPCR \< 3.0 mg/mg if the Day 1 (Baseline) ratio was \> 3.0 mg/mg; and stabilization of renal function (eGFR + or - 25% of Day 1 \[Baseline\] or serum creatinine within normal range). Estimated from the Kaplan-Meier Curve.
Query!
Timepoint [3]
0
0
Baseline to Week 52
Query!
Secondary outcome [4]
0
0
Percentage of Participants With uPCR > 3.0 mg/mg at Baseline Who Achieve uPCR <1.0 mg/mg at Week 52
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline (Day 1), Week 52
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Active Urinary Sediment at Baseline Who Have Inactive Urinary Sediment at Week 52
Query!
Assessment method [5]
0
0
Active urinary sediment is defined by 1 of the following (in the absence of a urinary tract infection or menses): \> 5 red blood cell/high power field (RBC/HPF) or above the reference range for the laboratory, and \> 5 white blood cell/high power field (WBC/HPF) or above the reference range for the laboratory, and presence of cellular casts (RBC or WBC). Inactive urinary sediment is defined as: \< 5 RBC/HPF and \< 5 WBC/HPF, or within the laboratory reference range, and no cellular casts (no RBC or WBC casts).
Query!
Timepoint [5]
0
0
Baseline, Week 52
Query!
Secondary outcome [6]
0
0
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Discontinuation During the Run-In Period
Query!
Assessment method [6]
0
0
AEs that had an onset on or after dosing of MMF on run-in Day 1 up to the first double-blind dose, or any pre-existing condition that worsened. AE: any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or results in a congenital anomaly/birth defect. An SAE may also be any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed above.
Query!
Timepoint [6]
0
0
Day 1 to Week 12
Query!
Secondary outcome [7]
0
0
Number of Participants With AEs, SAEs and AEs Leading to Study Discontinuation During the Double-Blind Period
Query!
Assessment method [7]
0
0
AEs that had an onset on or after dosing of BIIB023 or placebo, or any pre-existing condition that worsened. AE: any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or results in a congenital anomaly/birth defect. An SAE may also be any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed above.
Query!
Timepoint [7]
0
0
Week 12 to Week 56
Query!
Secondary outcome [8]
0
0
Duration of Renal Response in Participants Who Achieve Partial or Complete Renal Response at Any Time During the Study
Query!
Assessment method [8]
0
0
Number of days between first visit with response to last consecutive visit with partial or complete response. Complete renal response is defined as: (1) uPCR \<0.5 mg/mg with = 50% reduction of uPCR from Day 1 (Baseline) (from a 24 hour urine collection); and (2) eGFR within normal range. Partial renal response is defined as: (1) = 50% reduction in uPCR from Day 1 (Baseline; from a 24-hour urine collection) and, (2) with one of the following: (a) uPCR of \< 1.0 mg/mg if the Day 1 (Baseline) was = 3.0 mg/mg, or, (b) uPCR \< 3.0 mg/mg if the Day 1 (Baseline) ratio was \> 3.0 mg/mg; and stabilization of renal function (eGFR + or - 25% of Day 1 \[Baseline\] or serum creatinine within normal range). Estimated from the Kaplan-Meier Curve.
Query!
Timepoint [8]
0
0
up to Week 52
Query!
Eligibility
Key inclusion criteria
Key
* Documented diagnosis of systemic lupus erythematosus (SLE) according to current American College of Rheumatology (ACR) criteria. At least 4 ACR criteria must be documented, 1 of which must be a positive antinuclear antibody (ANA), anti Sm, or anti dsDNA antibody.
* Diagnosis of International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV lupus nephritis with either active or active/chronic disease, confirmed by biopsy within 3 months prior to Screening. Participants are permitted to have co existing Class V lupus nephritis. If a renal biopsy has not been performed within 3 months of the Screening Visit, one can be performed during the Screening Period after all other eligibility criteria have been confirmed. The local histological diagnosis must be confirmed by the central study pathologist.
* Must have proteinuria at Screening (from a 24 hour urine sample collection) defined as urinary protein:creatinine ratio (uPCR) >1.0 mg/mg.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Retinitis, poorly-controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia that is currently active and resulting from SLE at Screening
* Estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m^2 (calculated using the abbreviated Modification of Diet in Renal Disease equation) or the presence of oliguria or end-stage renal disease requiring dialysis or transplantation
* Subjects requiring dialysis within 12 months prior to Screening
* History of renal transplant
* Treatment with any biologic B-cell-depleting therapy (e.g., anti-CD20 [rituximab], anti-CD22 [epratuzumab], anti-BLyS/B-cell activating factor [e.g., briobacept, belimumab] therapy), or TACI-Ig within 12 months prior to Run-in Day 1.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
276
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Research Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3050 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Massachusetts
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
Argentina
Query!
State/province [10]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [11]
0
0
Argentina
Query!
State/province [11]
0
0
Tucuman
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Cordoba
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
La Plata
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
San Juan
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Leuven
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Liege
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
Mato Grosso
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Sao Paulo
Query!
Country [19]
0
0
Colombia
Query!
State/province [19]
0
0
Barranquilla
Query!
Country [20]
0
0
Colombia
Query!
State/province [20]
0
0
Bogota
Query!
Country [21]
0
0
Colombia
Query!
State/province [21]
0
0
Medelin
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Gironde
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Nord
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Paris 9
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Mainz
Query!
Country [27]
0
0
Hong Kong
Query!
State/province [27]
0
0
Hong Kong
Query!
Country [28]
0
0
Hong Kong
Query!
State/province [28]
0
0
Shatin
Query!
Country [29]
0
0
Hungary
Query!
State/province [29]
0
0
Budapest
Query!
Country [30]
0
0
Hungary
Query!
State/province [30]
0
0
Debrecen
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Pisa
Query!
Country [32]
0
0
Korea, Republic of
Query!
State/province [32]
0
0
Busan
Query!
Country [33]
0
0
Korea, Republic of
Query!
State/province [33]
0
0
Gyeonggi-do
Query!
Country [34]
0
0
Malaysia
Query!
State/province [34]
0
0
Sarawak
Query!
Country [35]
0
0
Malaysia
Query!
State/province [35]
0
0
Ipoh
Query!
Country [36]
0
0
Malaysia
Query!
State/province [36]
0
0
Kuala Lumpur
Query!
Country [37]
0
0
Malaysia
Query!
State/province [37]
0
0
Pulau Pinang
Query!
Country [38]
0
0
Malaysia
Query!
State/province [38]
0
0
Selangor Darul Ehsan
Query!
Country [39]
0
0
Malaysia
Query!
State/province [39]
0
0
Selangor
Query!
Country [40]
0
0
Mexico
Query!
State/province [40]
0
0
Coahuila
Query!
Country [41]
0
0
Mexico
Query!
State/province [41]
0
0
Cuauhtemoc
Query!
Country [42]
0
0
Mexico
Query!
State/province [42]
0
0
Leon
Query!
Country [43]
0
0
Mexico
Query!
State/province [43]
0
0
Mexico City
Query!
Country [44]
0
0
Mexico
Query!
State/province [44]
0
0
San Luis Potosi
Query!
Country [45]
0
0
Peru
Query!
State/province [45]
0
0
Lima
Query!
Country [46]
0
0
Philippines
Query!
State/province [46]
0
0
Manila
Query!
Country [47]
0
0
Philippines
Query!
State/province [47]
0
0
Quezon City
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Lodz
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Wroclaw
Query!
Country [50]
0
0
Portugal
Query!
State/province [50]
0
0
Coimbra
Query!
Country [51]
0
0
Russian Federation
Query!
State/province [51]
0
0
Moscow
Query!
Country [52]
0
0
Russian Federation
Query!
State/province [52]
0
0
Saint Petersburg
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Sagunto
Query!
Country [54]
0
0
Thailand
Query!
State/province [54]
0
0
Bangkok
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Biogen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of the study is to assess the efficacy of BIIB023 as an add-on treatment to background therapy compared with placebo in combination with background therapy in the treatment of participants with active, biopsy-proven lupus nephritis. The secondary objectives of this study are to assess the safety and tolerability of BIIB023 compared with placebo in this study population.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01499355
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Biogen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01499355
Download to PDF